Skip to main content

Table 4 Evaluation of risks for colorectal cancer

From: High expression of FABP4 and FABP6 in patients with colorectal cancer

Variable Unadjusted P value Adjusted P value
OR (95% CI) OR (95% CI)
BMI (kg/m2) 1.499 (0.710, 3.166) 0.289 --- ---
WHR 2.138 (1.002, 4.584) 0.037 2.084 (0.949, 4.578) 0.047
SBP (mmHg) 1.286 (0.815, 1.641) 0.055 1.258 (0.565, 2.802) 0.575
DBP (mmHg) 1.372 (0.993, 1.707) 0.051 1.034 (0.856, 1.413) 0.064
TCH (mmol/L) 0.522 (0.209, 1.307) 0.165 --- ---
TG (mmol/L) 0.927 (0.508, 1.692) 0.805 --- ---
LDL-C (mmol/L) 4.301 (3.271, 5.432) < 0.001 4.197 (3.144, 5.393) < 0.001
HDL-C (mmol/L) 0.078 (0.028, 0.218) < 0.001 0.124 (0.057, 0.274) < 0.001
FPG (mmol/L) 0.979 (0.274, 3.493) 0.974 --- ---
FABP4 (pg/ml) 2.141 (1.352, 3.074) < 0.001 1.916 (1.340, 2.492) < 0.001
FABP6 (pg/ml) 2.767 (1.517, 3.826) < 0.001 2.162 (1.046,1.078) < 0.001
CEA (ng/ml) 1.940 (1.038, 3.479) 0.026 1.713 (1.026, 3.236) 0.040
CA19-9 (U/ml) 3.516 (0.938, 6.186) 0.062 --- ---
Family history of CRC 7.298 (5.210, 9.747) < 0.001 5.119(3.940, 7.569) < 0.001
  1. Adjusted for WHR, SBP, DBP, LDL-C, HDL-C, CEA, family history of CRC; OR odd ratio, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, WHR waist:hip ratio, TCH total cholesterol, TG triglyceride, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, FPG fasting plasma glucose, FABP4 fatty acid-binding proteins 4, FABP6 fatty acid-binding proteins 6, CEA carcinoembryoni, CA19-9 carbohydrate antigen 19-9